TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025
- Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barring positive feedback from regulatory authorities, the company hopes to develop TSC-101 for AML, MDS, ALL patients who undergo HSCT in a pivotal study in the 2nd half of 2025. The company is developing multiplex TCR-Ts for treatment of patients with solid tumors, with phase 1 PLEXI-T trial data anticipated in the second half of 2025.
- 03/07/2025
|
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
- TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.21 per share a year ago.
- 03/05/2025
|
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66 th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program; TSC-202-A0201 targeting MAGE-A4 on HLA-A*02:01 Closed $30 million registered direct offering at 37% premium with long-standing, supportive shareholder Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2024, and provided a business update.
- 03/05/2025
|
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
- WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the TD Cowen 45th Annual Health Care Conference being held at the Marriott Copley Place in Boston, MA on Wednesday, March 5, 2025 at 1:10 p.m. Eastern Time.
- 02/27/2025
|
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
- WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time.
- 02/18/2025
|
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
- TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism.
- 02/10/2025
|
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks
- The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 01/10/2025
|
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
- WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale of approximately $30 million of pre-funded warrants to purchase up to an aggregate of 7,500,000 shares of its voting common stock at a price of $4.00 per pre-funded warrant, each exercisable to purchase one share of voting common stock at an exercise price of $0.0001 per share, representing a premium of 37% to the last closing price of TScan Therapeutics' common stock, and a 34% premium over the 10-day volume weighted average closing price. The financing is expected to close on or about December 27, 2024, subject to customary closing conditions.
- 12/26/2024
|
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
- New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029
- 12/23/2024
|
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
- To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14)
- 12/09/2024
|
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
- WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced it has been named one of the Top Places to Work in Massachusetts in the 17th annual, employee-based survey from The Boston Globe. The 2024 Top Places to Work issue was published online at Globe.com/TopPlaces and will appear in Globe Magazine on Sunday, December 8, 2024.
- 12/05/2024
|
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
- Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial
- 12/02/2024
|
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
- TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.24 per share a year ago.
- 11/12/2024
|
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
- TScan Therapeutics (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 11/07/2024
|
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
- All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT with reduced intensity conditioning Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, at 8:00 a.m.
- 11/05/2024
|
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
- WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually.
- 10/04/2024
|
TScan Therapeutics to Participate in Upcoming Investor Conferences
- WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
- 08/29/2024
|
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates
- TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago.
- 08/12/2024
|
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning
- 08/12/2024
|
TScan Therapeutics Announces Updates to its Board of Directors
- Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors
- 06/14/2024
|
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
- WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 5, 2024 at 11:00 a.m. Eastern Time.
- 05/30/2024
|
TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
- RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning
- 05/29/2024
|
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
- TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.93 per share a year ago.
- 05/13/2024
|
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of >10 months Closed upsized underwritten public offering with gross proceeds of $167.8 million, extending runway into the fourth quarter of 2026 WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
- 05/13/2024
|
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
- Patient dosed with TSC-20 3 -A0201 targeting cancer-associated antigen PRAME On-track to report initial data from the solid tumor clinical trial in 2024 WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been dosed in the Company's Phase 1 trial evaluating TCR-T therapy for the treatment of solid tumors.
- 05/09/2024
|
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
- TScan Therapeutics (TCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/01/2024
|
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
- WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago, IL as well as virtually.
- 04/24/2024
|
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
- WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the underwriters of its previously announced public offering, which closed on April 19, 2024, have partially exercised their over-allotment option to purchase an additional 2,485,487 shares of its voting common stock at the public offering price of $7.13 per share, less underwriting discounts and commissions. After giving effect to the option closing, the total number of shares sold by the Company in the offering were 4,958,068 shares, which along with pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock, resulted in aggregate gross proceeds to the Company of approximately $167.8 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
- 04/24/2024
|
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
- WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11 in Baltimore, MD as well as virtually.
- 04/22/2024
|
TScan Therapeutics Announces Closing of Upsized Public Offering
- WALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the closing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasdaq Global Market on April 16, 2024, and pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock at a price to the public of $7.1299 per pre-funded warrant to purchase one share of the voting common stock, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant. In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to TScan from this offering were approximately $150.1 million, prior to any exercise of the underwriters' option to purchase additional shares of voting common stock and before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan.
- 04/19/2024
|
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
- WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of the market price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasdaq Global Market on April 16, 2024, and pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock at a price to the public of $7.1299 per pre-funded warrant to purchase one share of the voting common stock, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant. In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to TScan from this offering are expected to be approximately $150.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan, assuming no exercise of the underwriters' option to purchase additional shares of voting common stock. The offering is expected to close on or about April 19, 2024, subject to customary closing conditions.
- 04/17/2024
|
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
- WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase shares of voting common stock. All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan. TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 04/16/2024
|
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
- Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex therapy
- 04/16/2024
|
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.
- Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development
- 04/08/2024
|
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 2:15 p.m. Eastern Time.
- 04/02/2024
|
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
- Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts.
- 03/17/2024
|
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
- TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.78 per share a year ago.
- 03/06/2024
|
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are relapse-free and show complete donor chimerism
- 03/06/2024
|
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
- WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference being held at the Marriott Copley Place in Boston on Wednesday, March 6, 2024 at 9:10 a.m. Eastern Time.
- 02/28/2024
|
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
- All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101
- 02/26/2024
|
TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?
- TScan Therapeutics, Inc. (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 02/19/2024
|
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
- TScan's abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of initial data from a large prospective clinical trial assessing the relationship between donor chimerism and risk of relapse WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®) on Monday, February 26, 2024, at 8:00 a.m.
- 02/14/2024
|
TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value
- Prevention relapse data from phase 1 study, using TSC-100/TSC-101 for HLA A*02:01 positive AML, MDS, and ALL patients, is expected to be released in 2024. Results from T-Plex [multiple TCR-Ts] targeting patients' solid tumors in phase 1 study are expected to be released in 2024. Amgen's multi-year collaboration deal brought in an upfront $30 million payment, $500 million possible milestone payments, and tiered royalties; First targeting Crohn's Disease and possibly later Ulcerative Colitis.
- 12/27/2023
|
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
- No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical intervention
- 12/09/2023
|
Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why
- TScan Therapeutics, Inc. (TCRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 12/06/2023
|
Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect?
- The mean of analysts' price targets for TScan Therapeutics, Inc. (TCRX) points to a 62.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 12/01/2023
|
TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy?
- Does TScan Therapeutics, Inc. (TCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 11/27/2023
|
TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why
- TScan Therapeutics, Inc. (TCRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
- 11/20/2023
|
What Makes TScan Therapeutics, Inc. (TCRX) a New Buy Stock
- TScan Therapeutics, Inc. (TCRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 11/15/2023
|
TScan Therapeutics: That Recent Amgen Deal Is The Only Point Of Interest
- TScan Therapeutics is developing TCR T-cell therapies for cancer using a transposon-based T cell engineering method. The company aims to target a broader patient population by addressing a wide range of human leukocyte antigen (HLA) types. TScan has a partnership with Amgen and has a sufficient cash balance to last for 6-7 quarters.
- 10/14/2023
|
TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why
- TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 10/12/2023
|
TScan Therapeutics to Participate in Upcoming Investor Conferences
- WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in the following upcoming investor conferences:
- 09/05/2023
|
TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know
- TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 08/16/2023
|
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
- TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.63 per share a year ago.
- 08/10/2023
|
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
- Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation
- 05/17/2023
|
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
- TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.67 per share a year ago.
- 05/10/2023
|
3 Top Strategies for Maximizing Penny Stock Profits Right Now
- Use these strategies to maximize your penny stocks profits The post 3 Top Strategies for Maximizing Penny Stock Profits Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/10/2023
|
TScan Therapeutics stock soars after Amgen collaboration on Crohn's disease treatment that could bring in more than $500 million
- Shares of TScan Therapeutics Inc. TCRX powered up 43.1% in premarket trading Tuesday, after the biopharmaceutical company announced a collaboration with Amgen Inc. AMGN to treat Crohn's disease that could be worth more than $500 million to TScan. Amgen shares slipped 0.1% ahead of the open.
- 05/09/2023
|
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
- WALTHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the Barclays Global Healthcare Conference being held at the Loews Miami Beach Hotel in Miami Beach, FL on Wednesday, March 15, 2023 at 4:05 p.m. Eastern Time.
- 03/13/2023
|
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
- WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023, at 3:30 p.m. Eastern Time.
- 02/21/2023
|
Best Penny Stocks To Buy? 5 To Watch After Big News This Week
- Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?
- 01/23/2023
|
TScan Therapeutics to Participate in Upcoming Investor Conferences
- WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in the following upcoming investor conferences:
- 09/22/2022
|
TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
- WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference being held at the Sheraton New York in New York, NY on Wednesday, September 14, 2022 at 12:55 p.m. ET.
- 09/07/2022
|
TScan Therapeutics to Participate in Upcoming Investor Conferences
- WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
- 03/02/2022
|
TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference
- WALTHAM, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 12:00 p.m. Eastern Time.
- 02/10/2022
|
FDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic Malignancies
- The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies patients undergoing allogeneic hematopoietic cell transplantation (HCT). The target of TSC-100 is the minor histocompatibility antigen HA-1, which is a lineage-specific antigen found on blood cells.
- 01/24/2022
|
TScan Therapeutics to Participate in Upcoming Investor Conferences
- WALTHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate virtually at the following upcoming investor conferences:
- 11/11/2021
|
Wall Street Analysts Believe TScan Therapeutics, Inc. (TCRX) Could Rally 147%: Here's is How to Trade
- The mean of analysts' price targets for TScan Therapeutics, Inc. (TCRX) points to a 147.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 11/01/2021
|
TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations
- WALTHAM, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Heather Savelle as Vice President, Investor Relations. Ms. Savelle brings to TScan over 20 years of experience in corporate communications and investor relations.
- 10/05/2021
|
TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference
- WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:00 p.m. ET.
- 09/28/2021
|
TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer
- WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that Zoran Zdraveski, J.D., Ph.D. has been appointed as Chief Legal Officer.
- 09/09/2021
|
TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
- WALTHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 4:15 p.m. ET.
- 09/02/2021
|
TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
- Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs
- 08/19/2021
|
